Welcome to Precision Vaccinations News
1 天前 · Shigellosis. France's Airports Report Increased Odyssean Malaria CasesMalaria vaccines are available in Africa in 2024. 7,000 Dengue Deaths Confirmed in the AmericasPAHO reports about 12 million Dengue Cases in 2024. Measles Elimination in Europe and South-East Asia Gains Momentum Measles Outbreaks detected in 57 countries in 2024.
Adjuvanted and High-Dose Influenza Vaccines Offer Comparable …
17 小时之前 · As the 2024-2025 flu season ramps up in the United States, new data reaffirms the protections offered by various influenza vaccines. The results of the first pragmatic randomized study to evaluate the relative vaccine effectiveness of adjuvanted inactivated influenza vaccine (aIIV) compared to high-dose inactivated influenza vaccine (HD-IIV) for influenza prevention were published today.
Shigella Vaccine Candidate Awarded U.S. FDA Fast Track Designation
2 天之前 · Saint-Herblain (Precision Vaccinations News). A seldom-discussed global health threat may soon have a U.S. Food and Drug Administration (FDA)- approved vaccine available. Valneva SE and LimmaTech Biologics AG today announced that the U.S. FDA has granted Fast Track designation to Shigella4V (S4V), the world's most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate.
Cell-based Influenza Vaccination Offer Measurable Benefits
2 天之前 · US CDC 2024. (Precision Vaccinations News) CSL Seqirus today announced new data from several studies that reinforce the benefits of cell-based influenza vaccines among people. On October 16, 2024, Seqirus stated results from multiple real-world evidence studies over different seasons showed improved relative vaccine effectiveness of cell-based ...
Mpox Vaccine Found Safe and Effective in Adolescents
1 天前 · October 17, 2024 • 10:27 am CDT. from Pixabay 2024. (Precision Vaccinations News) A U.S. National Institutes of Health (NIH)-funded phase 2 clinical trial of a mpox vaccine in 229 adolescents found it was safe and well tolerated through study day 210, according to a planned interim analysis of study data. As of October 16, 2024, the NIH also ...
Shigella Vaccine Candidate Advancing in Clinical Trials
4 天之前 · October 14, 2024. Shigella4V tetravalent bioconjugate vaccine candidate prevents shigellosis infections. Pixabay 2024. (Precision Vaccinations News) Shigella, the leading cause of diarrheal deaths worldwide, is having a resurgence in 2024. Among young children, it is estimated that diarrhea caused by Shigella is responsible for about 446,000 ...
mRNA-Based Flu Shot Focuses on Improving Performance in …
April 4, 2024 • 9:47 am CDT. As influenza vaccine producers prepare for the 2024 - 2025 flu season, innovative vaccine candidates are progressing in clinical research, focused on enhancing efficacy and safety. CureVac N.V. today announced interim data from an ongoing Phase 2 study, which is part of the combined Phase 1/2 study of its seasonal ...
21-Valent Pneumococcal Conjugate Vaccine Recommendations …
2024年9月13日 · The U.S. Centers for Disease Control and Prevention (CDC) today published updated recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding the use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults. On September 12, 2024, the CDC's MMWR confirmed the U.S. Food and Drug Administration approved 21-valent pneumococcal conjugate vaccine (PCV) (PCV21 ...
Herpes Vaccine Candidate Advances in 2023 - Precision …
2023年1月8日 · When BioNTech SE announced that the first person was dosed in a first-in-human Phase 1 clinical trial with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1, there was much enthusiasm generated by millions of people. BioNTech's placebo-controlled, observer-blinded, two-dose-escalation study was launched on ...
Trivalent Influenza Vaccines Will Be Delivered for the 2024-2025 …
2024年3月6日 · CSL Seqirus today announced that it is fully equipped to deliver its influenza vaccine portfolio for the 2024-2025 U.S. season. The new vaccine will be based on the trivalent strains recommended by the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC), which confirmed the viral strain selection in a March 5, 2024 meeting.
- 某些结果已被删除